Skip to main content
. 2020 Oct 21;4(20):5107–5117. doi: 10.1182/bloodadvances.2020002737

Figure 2.

Figure 2.

csCIs of cardiovascular diseases for DLBCL survivors, Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated by levels of exposure to doxorubicin (N = 2600) and in the normal comparison group (N = 13 000) with non-cardiac death as a competing risk.